CpG oligodeoxynucleotide ligand potentiates the activity of the pVAX1‑Sj26GST

Lu,Jun; Jiang,Shan; Ye,Song; Deng,Yun; Ma,Shuai; Li,Chao‑Pin

doi:10.3892/br.2013.99

CpG oligodeoxynucleotide ligand potentiates the activity of the pVAX1‑Sj26GST

Authors:
- Jun Lu
- Shan Jiang
- Song Ye
- Yun Deng
- Shuai Ma
- Chao‑Pin Li
View Affiliations

Affiliations: Department of Pathogen Biology and Immunology, School of Medicine, Anhui University of Science and Technology, Huainan, Anhui 232001, P.R. China, Department of Mining Engineering, Huainan Vocational and Technical College, Huainan, Anhui 232001, P.R. China, Department of Pathogen Biology, Bengbu Medical College, Wuhu, Anhui 241002, P.R. China
Published online on: April 30, 2013 https://doi.org/10.3892/br.2013.99
Pages: 609-613

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Schistosomiasis is considered one of the most important neglected tropical diseases and remains a major public health problem in endemic countries. Toll‑like receptor (TLR) ligands have been investigated as potential vaccine adjuvants for tumor and virus immunotherapy. However, few TLR ligands affecting schistosoma vaccines have been characterized. In this study, we evaluated a TLR9 ligand (CpG oligodeoxynucleotide 1826, CpG) as an adjuvant for a partially protective DNA vaccine encoding a 26‑kDa glutathione S‑transferase of Schistosoma japonicum (pVAX1‑Sj26GST). Vaccination with pVAX1‑Sj26GST in combination with CpG inhibited Treg immunosuppressive function, upregulated the production of interferon (IFN)‑γ, tumor necrosis factor (TNF)‑α, interleukin (IL)‑4, IL‑10, IL‑2 and IL‑6, and decreased CD4+CD8+Foxp3+ expression in vitro, which may contribute to the escape from Treg‑mediated suppression during vaccination, allowing expansion of antigen‑specific T cells against pathogens. In conclusion, our data demonstrated that selective TLR ligand combination may increase protective efficacy against schistosomiasis, which may synergistically antagonize Treg‑mediated suppression.

View Figures

View References

1.	Hotez PJ, Brindley PJ, Bethony JM, King CH, Pearce EJ, et al: Helminth infections: the great neglected tropical diseases. J Clin Invest. 118:1311–1321. 2008. View Article : Google Scholar : PubMed/NCBI
2.	King CH: Toward the elimination of schistosomiasis. N Engl J Med. 360:106–109. 2009. View Article : Google Scholar : PubMed/NCBI
3.	Doenhoff MJ, Cioli D and Utzinger J: Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis. 21:659–667. 2008. View Article : Google Scholar : PubMed/NCBI
4.	Abdul-Ghani R, Loutfy N, el-Sahn A and Hassan A: Current chemotherapy arsenal for schistosomiasis mansoni: alternatives and challenges. Parasitol Res. 104:955–965. 2009. View Article : Google Scholar : PubMed/NCBI
5.	Fenwick A, Webster JP, Bosque-Oliva E, Blair L, Fleming FM, et al: The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002–2008. Parasitology. 136:1719–1730. 2009.PubMed/NCBI
6.	McManus DP and Loukas A: Current status of vaccines for schistosomiasis. Clin Microbiol Rev. 21:225–242. 2008. View Article : Google Scholar : PubMed/NCBI
7.	Bergquist NR, Leonardo LR and Mitchell GF: Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach? Trends Parasitol. 21:112–117. 2005. View Article : Google Scholar : PubMed/NCBI
8.	Aloysius MM, Mc Kechnie AJ, Robins RA, Verma C, Eremin JM, et al: Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs. J Transl Med. 7:182009. View Article : Google Scholar : PubMed/NCBI
9.	Toka FN, Suvas S and Rouse BT: CD4⁺CD25⁺T cells regulate vaccine-generated primary and memory CD8⁺T-cell responses against herpes simplex virus type 1. J Virol. 78:13082–13089. 2004.
10.	Wang X, Zhou S, Chi Y, Wen X, Hoellwarth J, et al: CD4⁺CD25⁺Treg induction by an HSP60-derived peptide SJMHE1 from Schistosoma japonicum is TLR2 dependent. Eur J Immunol. 39:3052–3065. 2009.
11.	Tang CL, Lei JH, Wang T, Lu SJ, Guan F, et al: Effect of CD4⁺CD25⁺regulatory T cells on the immune evasion of Schistosoma japonicum. Parasitol Res. 108:477–480. 2010.
12.	Ahmad G, Zhang W, Torben W, Noor Z and Siddiqui AA: Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice. Int J Infect Dis. 14:e781–e787. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Mosser DM and Zhang X: Interleukin-10: new perspectives on an old cytokine. Immunol Rev. 226:205–218. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Schmetterer KG, Neunkirchner A and Pickl WF: Naturally occurring regulatory T cells: markers, mechanisms, and manipulation. FASEB J. 26:2253–2276. 2012. View Article : Google Scholar : PubMed/NCBI
15.	LaRosa DF, Gelman AE, Rahman AH, Zhang J, Turka LA and Walsh PT: CpG DNA inhibits CD4⁺CD25⁺Treg suppression through direct MyD88-dependent costimulation of effector CD4⁺T cells. Immunol Lett. 108:183–188. 2007.PubMed/NCBI
16.	Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, et al: Toll-like receptor 8-mediated reversal of CD4⁺regulatory T cell function. Science. 309:1380–1384. 2005. View Article : Google Scholar : PubMed/NCBI
17.	Duthie MS, Windish HP, Fox CB and Reed SG: Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev. 239:178–196. 2011. View Article : Google Scholar : PubMed/NCBI
18.	Engel AL, Holt GE and Lu H: The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. Expert Rev Clin Pharmacol. 4:275–289. 2011. View Article : Google Scholar : PubMed/NCBI
19.	Farias LP, Cardoso FC, Miyasato PA, Montoya BO, Tararam CA, et al: Schistosoma mansoni Stomatin like protein-2 is located in the tegument and induces partial protection against challenge infection. PLoS Negl Trop Dis. 4:e5972010. View Article : Google Scholar
20.	Cardoso FC, Macedo GC, Gava E, Kitten GT, Mati VL, et al: Schistosoma mansoni tegument protein Sm29 is able to induce a Th1-type of immune response and protection against parasite infection. PLoS Negl Trop Dis. 2:e3082008. View Article : Google Scholar
21.	Napolitani G, Rinaldi A, Bertoni F, Sallusto F and Lanzavecchia A: Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol. 6:769–776. 2005. View Article : Google Scholar : PubMed/NCBI
22.	Liu G and Zhao Y: Toll-like receptors and immune regulation: their direct and indirect modulation on regulatory CD4⁺CD25⁺T cells. Immunology. 122:149–156. 2007. View Article : Google Scholar : PubMed/NCBI
23.	Walker LS: Regulatory T cells overturned: the effectors fight back. Immunology. 126:466–474. 2009. View Article : Google Scholar : PubMed/NCBI
24.	Andre S, Tough DF, Lacroix-Desmazes S, Kaveri SV and Bayry J: Surveillance of antigen-presenting cells by CD4⁺CD25⁺regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am J Pathol. 174:1575–1587. 2009. View Article : Google Scholar : PubMed/NCBI
25.	Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, et al: TNF downmodulates the function of human CD4⁺CD25hi T-regulatory cells. Blood. 108:253–261. 2006. View Article : Google Scholar : PubMed/NCBI
26.	Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P and Yamaguchi T: Regulatory T cells: how do they suppress immune responses? Int Immunol. 21:1105–1111. 2009. View Article : Google Scholar : PubMed/NCBI
27.	Buckner JH: Mechanisms of impaired regulation by CD4(+) CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 10:849–859. 2010.
28.	Lu LF and Rudensky A: Molecular orchestration of differentiation and function of regulatory T cells. Genes Dev. 23:1270–1282. 2009. View Article : Google Scholar : PubMed/NCBI
29.	Zhu Q, Egelston C, Gagnon S, Sui Y, Belyakov IM, et al: Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest. 120:607–616. 2010. View Article : Google Scholar : PubMed/NCBI